WLC

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
Thursday, March 28, 2024
NMIBC, Biopsy, BLC, TURBT, Patient, Skin, WLC, MD, Cancer, Bladder cancer, Pathology

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Retrieved on: 
Thursday, March 28, 2024
NMIBC, Biopsy, BLC, TURBT, Patient, Skin, WLC, MD, Cancer, Bladder cancer, Pathology

OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.

Key Points: 
  • OSLO, Norway, March 28, 2024 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week.
  • This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
  • The authors conclude that regardless of race, BLC increased the detection of bladder cancer when combined with WLC.
  • However, the difference was more pronounced in Asian patients: "Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

Retrieved on: 
Monday, January 29, 2024
WLC, BLC, ASCO, RCT, CIS, Patient, Randomized controlled trial, Diagnosis, Society, Bladder cancer, RWS

The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.

Key Points: 
  • The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.
  • A total of 114 patients were in the full analysis set.
  • Nineteen patients were included in the real-world study (RWS).
  • The new drug application (NDA) for APL-1706 was accepted by the National Medical Products Administration (NMPA) in November 2023.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023
NDA, RCT, National Medical Products Administration, WLC, NMIBC, Carcinoma, NMPA, Bladder cancer, Patient, SIU, CIS, SSE, Isabella Tree, BLC, Standard of care, Congress, Cystoscopy, Pharmaceutical industry, Medical imaging, Photocure, Hexyl aminolevulinate hydrochloride

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

T1 E1 Network Test Solution Capabilities

Retrieved on: 
Thursday, November 2, 2023
CAS, DCE, Linux, PC, WCS, DTE, GSM, Analyser, Command-line interface, SSH, FXS, GL, Telephone, Python, Unix, WLC, PPP, Maintenance, USB, Frame Relay, SS7, Microsoft Windows, Telecom, PowerShell, ISDN, SS1, FXO, Probe, Collection, HDLC, Automation, Data analysis, Communication, Console, Emulation, Mobile phone, Video game, Internet service provider, Computer data storage, Computer network

“GL's tProbe™ is a test and measurement device for T1 E1 networks.

Key Points: 
  • “GL's tProbe™ is a test and measurement device for T1 E1 networks.
  • GL's Windows Client/Server (WCS) software allows T1 E1 analysis and emulation cards with remote operation, automation, and multi-site connectivity capabilities.
  • It sends commands to T1 E1 WCS servers and shows the responses in Console, PowerShell, or Terminal Windows.
  • Available with Dual T1 or E1, FXO, FXS, DTE and DCE interfaces
    Bit Error Rate Testing over all timeslots.

Incline Partners with White Label Communications

Retrieved on: 
Tuesday, October 24, 2023
Member of the Scottish Parliament, Incline, MSP, SMS, Managed services, Partnership, WLC, Atlas, The Company, Voice over IP

PITTSBURGH, Oct. 24, 2023 /PRNewswire/ -- Incline Equity Partners ("Incline"), a leading private equity firm dedicated to investing across the middle market, is pleased to announce its partnership with White Label Communications ("WLC" or the "Company"), a provider of private label communication solutions to Managed Service Providers ("MSPs").

Key Points: 
  • PITTSBURGH, Oct. 24, 2023 /PRNewswire/ -- Incline Equity Partners ("Incline"), a leading private equity firm dedicated to investing across the middle market, is pleased to announce its partnership with White Label Communications ("WLC" or the "Company"), a provider of private label communication solutions to Managed Service Providers ("MSPs").
  • Our partnership with Incline will provide continued investment and expertise to advance our technology platform.
  • "White Label Communications was founded in 2011 to create a simple solution for private label unified communications," said Tom Joseph, Founder and CEO of WLC.
  • "Our partnership with Incline will provide continued investment and expertise to advance our technology platform, further enabling our MSP partners to grow their businesses."

Whistleblower Law Collaborative Sponsoring and Speaking at The Anti-Fraud Coalition 23rd Annual Conference

Retrieved on: 
Friday, October 13, 2023
Linda, Post-election lawsuits related to the 2020 U.S. presidential election, Multimedia, Knowledge, Justice, Conference, Security (finance), Uganda Advanced Certificate of Education, Scourge, False Claims Act, FCA, Medicare Part D, WLC, Justice minister, Certified Paralegal, Council, Complaint, Medicare, Medicare Advantage, Paralegal, TAF, Global Jurist of the Year Award, Part, Crossing the Bridge, Pharmaceutical industry, Fraud

BOSTON, Oct. 13, 2023 /PRNewswire/ -- The Anti-Fraud Coalition (TAF Coalition) 23rd Annual Conference will be held October 18-20, 2023, in Washington, D.C. Whistleblower Law Collaborative (WLC) will once again be an active participant in the Conference both as a proud sponsor and with members speaking on important and timely topics.

Key Points: 
  • BOSTON, Oct. 13, 2023 /PRNewswire/ -- The Anti-Fraud Coalition (TAF Coalition) 23rd Annual Conference will be held October 18-20, 2023, in Washington, D.C. Whistleblower Law Collaborative (WLC) will once again be an active participant in the Conference both as a proud sponsor and with members speaking on important and timely topics.
  • Speaking at the TAF Coalition Conference will be Attorney Erica Blachman Hitchings , a member of TAF's President's Council and Government Relations Committee, Attorney Linda C. Severin , and Advanced Certified Paralegal, Kelly Shivery.
  • The panel is entitled, Every Case is a Part C Case Now: How Relators Can Help Stymie the Scourge of Fraud in the Medicare Advantage Space.
  • She and her fellow panelists will explore the recent case law developing around the Anti-Kickback Statute, particularly with respect to causation and damages.

International Rainy-Lake of the Woods Watershed Board Water Levels Committee Releases the Final 2022 Post-Flood Report

Retrieved on: 
Tuesday, October 10, 2023
International Joint Commission, Water quality, All Gates Open: The Story of Can, Report, IJC, Woods, WLC, International, Longevity, Moose River (Namakan Lake), Water, Dam

INTERNATIONAL FALLS, MN and FORT FRANCES, ON, Oct. 10, 2023 /PRNewswire/ - The International Rainy-Lake of the Woods Watershed Board (IRLWWB) Water Levels Committee (WLC) released its 2022 Post-Flood Report: A Report on High Water Levels in the Rainy River Basin .

Key Points: 
  • INTERNATIONAL FALLS, MN and FORT FRANCES, ON, Oct. 10, 2023 /PRNewswire/ - The International Rainy-Lake of the Woods Watershed Board (IRLWWB) Water Levels Committee (WLC) released its 2022 Post-Flood Report: A Report on High Water Levels in the Rainy River Basin .
  • In the spring and summer of 2022, the Namakan Chain of Lakes and Rainy Lake reached some of the highest water levels on record.
  • The intensity and longevity of the spring precipitation caused flows in the tributaries of the Rainy River watershed to remain at high or close to peak levels from late April to mid-June.
  • Rainy Lake's All-Gates Open level is 337.90 (1108.6 ft) and Namakan Lake's All-Gates Open level is 341.10 m (1119.1 ft).

Whistleblower Law Collaborative LLC Celebrates 20 Years of Representing Whistleblowers

Retrieved on: 
Friday, October 6, 2023
Linda, Woman, Multimedia, Fraud, Public, False Claims Act, Government, FCA, Safety, WLC, Accusative case, Growth, History, Lawyer, Thomson Reuters, AmerisourceBergen, Pharmaceutical industry, Practice of law, Mallinckrodt

BOSTON, Oct. 6, 2023 /PRNewswire/ -- Whistleblower Law Collaborative LLC , an award-winning Boston based firm representing whistleblowers nationwide, is celebrating its 20th anniversary .

Key Points: 
  • BOSTON, Oct. 6, 2023 /PRNewswire/ -- Whistleblower Law Collaborative LLC , an award-winning Boston based firm representing whistleblowers nationwide, is celebrating its 20th anniversary .
  • In an anniversary video , WLC celebrates its history, recounts its successes and growth, and looks forward to its future.
  • and Suzanne E. Durrell , both former government prosecutors, joined forces in 2003 to represent whistleblowers in in qui tam actions under the False Claims Act.
  • Whistleblower Law Collaborative LLC devotes its practice entirely to representing whistleblowers.